Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h): sc-400229-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) and Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the AGTR1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Angiotensin Receptor/AT1/AGTR1 Antibody (G-3): sc-515884
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) | sc-400229-ACT | 20 µg | $397.00 | |||
Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h2) | sc-400229-ACT-2 | 20 µg | $397.00 |
AGTR1 encodes the angiotensin II type 1 receptor (AT1), a seven-transmembrane GPCR that mediates most canonical angiotensin II signaling in cardiovascular and renal tissues. Upon ligand binding, AT1 couples predominantly to Gq/11 to activate phospholipase C, calcium mobilization, and PKC, and it can engage MAPK/ERK, JAK/STAT, ROS-generating pathways, and β-arrestin–dependent signaling that modulates receptor desensitization and trafficking. These cascades regulate vasoconstriction, aldosterone secretion, sodium and water homeostasis, vascular remodeling, inflammation, and fibrosis. Dysregulated AGTR1 activity and expression have been implicated in hypertension, cardiac hypertrophy, atherosclerotic processes, and chronic kidney disease–associated remodeling, making it a widely studied node in RAAS pathway biology.
Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous AGTR1 expression without altering the underlying DNA sequence.
Angiotensin Receptor/AT1/AGTR1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the AGTR1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the AGTR1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Angiotensin Receptor/AT1/AGTR1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native AGTR1 locus and enabling the study of Angiotensin Receptor/AT1/AGTR1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Angiotensin Receptor/AT1/AGTR1 pathway restoration in tumor cells with silenced or reduced AGTR1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.